Dishman Carbogen Amcis Ltd

Allotment Details

• Board approves allotment of 3,800 senior secured NCDs.
• Face value Rs 1,00,000 per debenture; total Rs 38 crore.
• Issuance through private placement.
• Allotment date: 15 October 2026.
• Maturity: 15 April 2028 or early redemption date.

Debt / Securities Update

• Allotted 1,500 senior secured NCDs; rated, listed, transferable, taxable.
• Aggregate value Rs 15 crore; private placement.
• Date of allotment: 28 September 2026.
• Final maturity: 28 March 2028 or early redemption date.
• Board approval by Management Committee on 28 September 2026.

Dishman Carbogen Amcis Ltd — Trading Window closed from 1st October, 2026; will be opened 48 hours after the announcement of the Un-Audited Financial Results of the Company for the quarter and half year ending 30th September, 2026.

FDA inspection result

• CARBOGEN AMCIS AG's Vionnaz, Switzerland site completed its first US FDA inspection with no observations.
• All company sites worldwide remain approved by major regulatory agencies.

AGM Details

• AGM date: 30 September 2026; time: 3:00 PM IST; mode: VC/OAVM.
• Resolutions include ordinary and special businesses as set out in the AGM notice.
• Electronic voting facility available; remote e-voting details published in the notice.
• Notice to Members sent electronically; available on company website and stock exchanges.

AGM details

• AGM date: 30 September 2026; time: 15:00 hours; mode: VC/OAVM.
• Notice of AGM and Annual Report to be sent electronically to registered shareholders.
• Members can attend and vote remotely via e-voting during the AGM.

AGM Details

• AGM scheduled for 30 September 2026 at 15:00 IST via VC/OAVM.

Cessation of Senior Management

• Deepak Ram Chandra Mittal, Vice President (Operation), cessation/relieving effective 27 August 2026.

Financial Performance

• Revenue for quarter ended 30 Jun 2026: INR 6,776 million, down 4% YoY.
• EBITDA: INR 600 million; vs INR 1,406 million prior year.
• PBT: loss before tax INR 512 million; tax INR 66 million.
• FX impact: INR 117.3 million.
• CDMO revenue: INR 5,343 million; Marketable Molecules: INR 1,432 million.
• ADC revenue in quarter: INR 150 crores.
• CapEx: CHF 4.9 million; net debt excl. lease: CHF 153.6 million.
• Consolidated goodwill: > INR 4,000 crores; standalone goodwill ~INR 550 crores.

Operations and Segments

• Marketable Molecules margin normalized to INR 18.6 million due to higher cholesterol sales.
• Naroda MFDS Korea inspection completed; MFDS Korea and US FDA observation ongoing.
• Two EDQM CEPs granted in Europe; commercial product approvals in Myanmar.
• Commercial transfers from Switzerland to India progressing; Bavla/Naroda CDMO activity rising.

Balance Sheet and Cash Flow

• CapEx in Q1: CHF 4.9 million.
• Net debt excluding lease liabilities: CHF 153.6 million as of 30 Jun 2026.
• Goodwill on consolidated basis: > INR 4,000 crores; Indian standalone goodwill ~INR 550 crores.

Outlook and Guidance

• FY27 revenue: single-digit growth; EBITDA margin similar to last year.
• FY28-29: at least double-digit growth in France and India; >10% revenue YoY.
• EBITDA margin target FY28-29: 25-26%.
• Fundraising: promoter ECB up to CHF 200 million; 4% all-inclusive; 10-year tenor; 60-90 days.
• Net debt end-FY27: ~CHF 140-150 million.

Q&A Highlights

• Debt/refinancing: promoter infusion via ECB; to prepay high-cost debt; multiple tranches.
• Indian entity revenue: +30-35% in FY27; margins ~10% operating.
• Phase III: one molecule approved and moved to commercial; none in Q1.
• ECB RBI approval: obtained; ECB funds to be infused directly to Indian entity.

Risks and Opportunities

• Top-line lumpiness inherent in development-heavy CDMO model; focus on 2–3 year horizon.
• Destocking by customers may affect quarterly visibility.
• Regulatory actions and EDQM/India-site issues influence timing of launches.

Meeting Details

• Date and time: 17 August 2026 at 17:00 IST.
• Type and mode: audio earnings conference call; group, virtual.
• Organizer: Dishman Carbogen Amcis Limited.
• Topic: discuss quarterly results for Q1 FY2026-27.
• Quarter ended: 30 June 2026.

Participants

• Key company participants: not disclosed in the filing.

Purpose

• Purpose: discuss Q1 FY2026-27 results and June 2026 performance.

Additional Notes

• Audio recording of the conference call is available on the company website.